Thirteen-year, long-term efficacy of interferon 2α and interleukin 2-based home therapy in patients with advanced renal cell carcinoma
Article first published online: 19 AUG 2002
Copyright © 2002 American Cancer Society
Volume 95, Issue 5, pages 1045–1050, 1 September 2002
How to Cite
Atzpodien, J., Hoffmann, R., Franzke, M., Stief, C., Wandert, T. and Reitz, M. (2002), Thirteen-year, long-term efficacy of interferon 2α and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer, 95: 1045–1050. doi: 10.1002/cncr.10783
- Issue published online: 19 AUG 2002
- Article first published online: 19 AUG 2002
- Manuscript Accepted: 3 MAY 2002
- Manuscript Revised: 12 FEB 2002
- Manuscript Received: 22 AUG 2001
- Deutsche Krebshilfe
- Gesellschaft zur Förderung Immunologischer Krebstherapien e.V
- renal cell carcinoma;
- interleukin 2;
- interferon α
The goal of the current report was to demonstrate the long-term efficacy of outpatient subcutaneous (sc) interferon α (IFN-α) and sc interleukin 2 (IL-2)-based combination regimens in patients with metastatic renal cell carcinoma.
In three consecutive clinical trials, 443 patients received combined sc IFN-α and sc IL-2 (n = 97 patients); combined sc IFN-α, sc IL-2, and intravenous (iv) 5-fluorouracil (5-FU) (n = 260 patients); or combined sc IFN-α, sc IL-2, and iv 5-FU with oral 13cis-retinoic acid (n = 86 patients).
The median overall survival was 21+ months. The 2-year, 5-year, and 13-year survival rates were calculated at 45.26%, 15.96%, and 8.96%, respectively. The median time to disease progression was 6 months. The 2-year, 5-year, and 13-year progression free survival rates were 17.84%, 9.54%, and 9.20%, respectively.
The current data suggest that combined outpatient sc IFN-α and sc IL-2, according to the Atzpodien regimen, achieves long-term survival benefits in a subset of patients with metastatic renal cell carcinoma, both with and without 13-cis-retinoic acid and/or 5-fluorouracil. Cancer 2002;95:1045–50. © 2002 American Cancer Society.